Gene · 10014
Papers2,885
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,885
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells. | Front Oncol | 2023 | 37886173 | PubTator, text mining | PubMed |
| Bedside to bench: the outlook for psychedelic research. | Front Pharmacol | 2023 | 37869749 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in kidney injury. | Clin Epigenetics | 2023 | 37865763 | PubTator, text mining | PubMed |
| Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study. | BMC Cancer | 2023 | 37858067 | PubTator, text mining | PubMed |
| MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis. | Front Oncol | 2023 | 37854681 | PubTator, text mining | PubMed |
Perturbation of 3D nuclear architecture, epigenomic aging and dysregulation, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 2-Metabolome, immunome, synaptome. | Front Psychiatry | 2023 | 37854446 | PubTator, text mining | PubMed |
| Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities. | Nucleic Acids Res | 2023 | 37843125 | PubTator, text mining | PubMed |
| The role of N6-methyladenosine (m6A) in kidney diseases. | Front Med (Lausanne) | 2023 | 37841018 | PubTator, text mining | PubMed |
| Epigenetic Modulators as Therapeutic Agents in Cancer. | Int J Mol Sci | 2023 | 37834411 | PubTator, text mining | PubMed |
| Histone and Histone Acetylation-Related Alterations of Gene Expression in Uninvolved Psoriatic Skin and Their Effects on Cell Proliferation, Differentiation, and Immune Responses. | Int J Mol Sci | 2023 | 37833997 | PubTator, text mining | PubMed |
| Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data. | Int J Mol Sci | 2023 | 37833875 | PubTator, text mining | PubMed |
| Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma. | BMC Cancer | 2023 | 37789275 | PubTator, text mining | PubMed |
| WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2. | Oncogenesis | 2023 | 37783676 | PubTator, text mining | PubMed |
| SIRT2 alleviated renal fibrosis by deacetylating SMAD2 and SMAD3 in renal tubular epithelial cells. | Cell Death Dis | 2023 | 37777567 | PubTator, text mining | PubMed |
| The Role of G Protein-Coupled Estrogen Receptor (GPER) in Vascular Pathology and Physiology. | Biomolecules | 2023 | 37759810 | PubTator, text mining | PubMed |
| How does NFAT3 regulate the occurrence of cardiac hypertrophy? | Int J Cardiol Heart Vasc | 2023 | 37753338 | PubTator, text mining | PubMed |
| Arachidonic acid metabolism in health and disease. | MedComm (2020) | 2023 | 37746665 | PubTator, text mining | PubMed |
| NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2. | J Neuropathol Exp Neurol | 2023 | 37742129 | PubTator, text mining | PubMed |
| FGF2 Alleviates Microvascular Ischemia-Reperfusion Injury by KLF2-mediated Ferroptosis Inhibition and Antioxidant Responses. | Int J Biol Sci | 2023 | 37705747 | PubTator, text mining | PubMed |
| Unlocking the potential of targeting histone-modifying enzymes for treating IBD and CRC. | Clin Epigenetics | 2023 | 37697409 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10014/papers?page=10